Stock Market & Financial Investment News

News Breaks September 28, 2012 10:00 EDT MYL, SNY Mylan launches generic versions of Sanofi's Avapro and Avalide tablets Mylan (MYL) announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Irbesartan Tablets USP, 75 mg, 150 mg and 300 mg, the generic version of Sanofi's (SNY) Avapro. The company also received final approval from the FDA for its ANDA for Irbesartan and Hydrochlorothiazide Tablets USP, 150/12.5mg and 300/12.5 mg, the generic version of Sanofi's Avalide. Mylan is shipping both products immediately. News For MYL;SNY From The Last 14 Days Check below for free stories on MYL;SNY the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. June 18, 2013 08:38 EDT SNY Sanofi management to meet with JPMorgan Subscribe for More Information 08:36 EDT MYL Elan shares could be worh $19 in a buyout, says Jefferies Jefferies raised its price target for shares of Elan (ELN) to $19 from $14, reflecting what it sees as the value of the company in a takeout scenario. The firm says Elan management suggested they would be open to sale in the $15-$20 per share range. Jefferies believes a high taxpaying suitor could pay the upper end of that range, and lists Allergan (AGN), Regeneron (REGN), Vertex (VRTX), Alexion (ALXN), Zoetis (ZTS), Mylan (MYL) and Perrigo (PRGO) as potential acquirers for Elan. Shares of Elan are up 13c to $13.62 in pre-market trading after Royalty Pharma announced that its buyout proposal for the company has expired. June 17, 2013 13:20 EDT MYL Supreme Court rules generic drug makers can be sued over 'pay to delay' Subscribe for More Information 11:54 EDT MYL Supreme Court ruling a modest negative for generics, says Leerink Subscribe for More Information 08:36 EDT MYL InSite Vision to join Merck, Pfizer patent suit against Mylan InSite Vision (INSV) announced that it will join Merck (MRK) and Pfizer (PFE) in filing a patent infringement lawsuit against Mylan Pharmaceuticals (MYL). Mylan recently filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking to market a generic version of AzaSite before expiration of the patents covering AzaSite and its use. AzaSite is marketed by Merck in the U.S. On May 26, 2011, InSite and Merck filed a similar patent infringement lawsuit against Sandoz. A trial date for the Sandoz ANDA suit has been set for July 11, 2013. The companies have agreed that Merck will take the lead in prosecuting both lawsuits. Each company will be responsible for their own legal costs, with InSite assuming a monitoring role, the company said. June 13, 2013 17:23 EDT MYL Mylan files automatic mixed securities shelf Subscribe for More Information 11:02 EDT SNY Leerink's major pharma analyst holds an analyst/Industry conference call Subscribe for More Information June 12, 2013 13:47 EDT MYL Mylan sees buying back stock in near future, Bloomberg says Subscribe for More Information 13:31 EDT MYL Mylan could be interested in generic assets split from Pfizer, Bloomberg says 13:28 EDT MYL Mylan chairman said explored possible Hospira deal Bloomberg says Subscribe for More Information June 10, 2013 07:20 EDT SNY Biomed to host a conference Subscribe for More Information 07:03 EDT SNY Sanofi announces FDA approved sBLA for licensure of influenza vaccine Subscribe for More Information June 4, 2013 09:06 EDT SNY Merrimack Phase 1 research supports MM-121 potential for investigation Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.